Posted by Michael Wonder on 23 Jan 2019
ICER launches international collaborative to develop new methods to guide value-based pricing of potential cures
23 January 2019 - NICE in the UK and CADTH in Canada among international agencies participating; public input on key methodological issues is being accepted through 20 February 2019.
The Institute for Clinical and Economic Review (ICER) today announced a new project to develop and test alternative methods for the evaluation of potentially curative treatments and for translating the results of cost-effectiveness analyses into recommendations for value-based price benchmarks. In this work, ICER will collaborate with methodology experts, stakeholders, and several leading international health technology assessment (HTA) groups, including both the United Kingdom's National Institute for Health and Care Excellence (NICE) and the Canadian Agency for Drugs and Technologies in Health (CADTH).
The goal of this initiative is to ensure that assessment methods are tailored appropriately to the distinctive nature of the evidence base for potential cures. The initiative will inform ICER's 2019 update to its value assessment framework while seeking to build consensus across HTA groups in anticipation of a rising tide of gene therapies and other potential cures.
